NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
Clinical Trials
24 trialsNCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT03748953 2025-03-21
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
Takeda
Phase 3 Completed
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT02181413 2024-11-19
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Takeda
Phase 3 Completed
NCT03439293 2024-07-03
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda
Phase 2 Completed
NCT03733691 2023-10-25
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Oncotherapeutics
Phase 2 Terminated
NCT02312258 2023-09-21
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Takeda
Phase 3 Completed
NCT01564537 2023-03-10
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 3 Completed
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting
NCT05183139 2022-05-03
US MM-7
Takeda
Phase 4 Withdrawn
NCT03888534 2020-09-28
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Takeda
Phase 1 Withdrawn
NCT01953783 2020-08-26
Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
Takeda
Phase 1 Completed
NCT03608501 2020-01-14
IDEALL
Takeda
Phase 2 Withdrawn
NCT00830869 2019-09-09
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT00932698 2019-08-07
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
Takeda
Phase 1 Completed
NCT01830816 2019-06-10
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
Takeda
Phase 1 Completed
NCT01645930 2018-11-08
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 1 Completed
NCT01217957 2018-03-14
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT01335685 2018-01-23
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT00963820 2018-01-10
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
Takeda
Phase 1 Completed
NCT01454076 2017-11-01
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
Takeda
Phase 1 Completed
NCT01912222 2016-06-02
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT00893464 2015-11-11
A Study of IXAZOMIB in Adult Patients With Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed